Preclinical evidence

Study 1: Resveratrol improves lipid profile in hyperlipidemic mice

A study evaluated the ability of resveratrol to improve the plasma lipid levels of the hyper-lipidemic animal model. Resveratrol was administered in different doses (10, 20, and 40 mg/kg BW daily) for 6 weeks, and the effect of the supplementation on the levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were assessed. The supplementation resulted in reduced TC, TG, LDL-c, and atherogenic index of hyper-lipidemic mice in a dose-dependent manner. The authors concluded that resveratrol can effectively improve the atherogenic index and may support cardiovascular health.

Xie HC, Han HP, Chen Z, He JP. A study on the effect of resveratrol on lipid metabolism in hyperlipidemic mice. Afr J Tradit Complement Altern Med. 2013;11(1):209-212.

Study 2: Resveratrol improves lipid profile and atherogenic index in rat model of polycystic ovary

A study evaluated the effect of resveratrol supplementation on lipid profile and atherogenic index in the rat model of polycystic ovary syndrome. After the development of the polycystic condition, resveratrol 10 mg/kg was injected intraperitoneally for 28 days. The serum levels of total cholesterol, triglycerides, LDL-C (low-density lipoprotein-cholesterol), VLDL-C (Very low-density lipoprotein-cholesterol), HDL-C (High-density lipoprotein-cholesterol), and glucose were assessed, and the atherogenic index was calculated based on the lipid profile. The supplementation resulted in decreased serum levels of LDL-C, atherogenic index, and glucose (p<0.05) and increased the serum HDL-C level (p<0.05). The authors conclude that supplementation with resveratrol may improve the dyslipidemia status and may reduce the atherogenic index.

Ghowsi M, Khazali H, Sisakhtnezhad S. Effect of resveratrol on blood lipids and atherogenic index in rat model of polycystic ovary syndrome. iranian veterinary journal. 2019;15(3):48-57.

Study 3: Resveratrol improves hypoxic pulmonary hypertension by modulating immune response and improving antioxidant status in an animal model

A preclinical study investigated the efficacy of resveratrol to ameliorate the adverse effects of hypoxia in hypoxic pulmonary hypertension induced in Sprague-Dawley rats. The hypoxic rats were supplemented with resveratrol (40 mg/kg/day) for 28 days and the hemodynamic and pulmonary patho-morphology were measured to evaluate the efficacy of resveratrol to alleviate hypoxic pulmonary hypertension. The supplementation alleviated the right ventricular systolic pressure and pulmonary arterial remodeling induced by hypoxia. The supplementation also reduced the HIF-1 α expression, suppressed inflammatory cell infiltration around the pulmonary arteries, and decreased reactive oxygen species production induced by hypoxia. The study concluded that resveratrol may modulate hypoxic pulmonary hypertension through its anti-proliferation, anti-inflammation, and antioxidant effects.

Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int J Med Sci. 2016; 13(12):942-954